CellSens 1.11 - Discover a New Level of Simplicity
![](/46/pdcnewsitem/03/33/65/RgxR1PefRCHQ5jf.jpg)
Personalised automation is the key to managing complex multi-dimensional experiments, and the latest Olympus cellSens imaging software (version 1.11) seamlessly controls motorised hardware to allow effortless set-up of complex acquisition sequences and protocols. The unique Graphical Experiment Manager (GEM) interface allows the user to "draw" their experimental schematic on-screen with familiar “drag and drop” actions, enabling complete control and experimental set-up of motorised components and accessories with almost no need for training. The capabilities of this intuitive interface are now expanded to the control of motorised stages, enabling the easy automation of multi-position experiments such as individual scanning protocols performed at different positions on a multiwell plate.
Providing insights into a host of biological processes, additional new features of the software include online ratiometric analysis, delivering results in real time and control of rapid focusing devices for fast 3D applications, while also supporting the latest cameras and image-splitter components. From image acquisition to analysis, expanding the range of components compatible with cellSens presents new avenues of exploration within life science. Additional models of EMCCD and sCMOS cameras are now supported such as the Hamamatsu ImagEM X2 and the Andor Zyla 4.2, delivering rapid and sensitive imaging; while 3D applications benefit from the integrated control of piezo-driven devices, for ultra-fast Z-stacking and focusing. Multi-channel imaging of samples with fast dynamics is now supported through the use of an image splitter, with up to four emission channels acquired at the same precise moment. The exact synchronisation of multiple wavelengths also quickly produces reliable images for advanced applications such as FRET and ratiometric analysis. Moreover, ratiometric analysis can now be achieved “online”, enabling the real-time tracking and updating of ratiometric images and graphs during experiments.
These combined features make cellSens version 1.11 ideal for a range of life science imaging applications, enabling any user to rapidly and easily generate reliable results.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance